Developer docs
API playgroundTry for free, no card

Search company profiles

Nuance Pharma

Full company profile

uuid003idel

Namestring
Nuance Pharma
Legal namestring
优锐医药科技(上海)有限公司
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Nuance Pharma (also operating as Nuance Biotech, legal name 优锐医药科技(上海)有限公司) is a Shanghai-headquartered specialty care biopharmaceutical company founded in 2014 by Mark Lotter. The company operates a "dual-wheel model" that pairs self-sustaining commercial operations with late-stage clinical pipeline development across four therapeutic areas: respiratory disease (COPD, neonatal respiratory distress syndrome, and allergic rhinitis), emergency cardiac care, iron deficiency anemia, and post-operative pain management. End customers are primarily hospitals, healthcare providers, and patients across China and Asia Pacific markets.

The company's commercial portfolio includes NIFEREX (iron polysaccharide complex capsules), ISOKET (isosorbide dinitrate injection and spray), ELANTAN (isosorbide mononitrate sustained-release capsules), and OLPRINONE (olprinone hydrochloride) for heart failure — the latter three acquired through the 2021 Sino Health acquisition — alongside the recently launched Bentrio nasal spray for allergic rhinitis. The late-stage clinical pipeline features four differentiated assets: Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of PDE3 and PDE4 licensed from Verona Pharma, representing the first novel inhaled mechanism for COPD maintenance treatment in over 20 years; AeroFact, a non-invasive nasal surfactant delivery system for neonatal RDS combining bovine lung surfactant with Aerogen's patented PDAP aerosol technology; NTM-001 (ketorolac), a non-opioid alcohol-free IV infusion for post-operative pain licensed from Neumentum; and Actair, a sublingual immunotherapy tablet for house dust mite allergy licensed from Stallergenes Greer.

Nuance generates revenue through a mix of direct product sales in China and Asia Pacific, upfront licensing payments and milestone receipts from global partners (including a US$219 million Verona Pharma strategic collaboration), and ongoing royalties. Distribution is anchored by a strategic cooperation agreement with Shanghai Pharmaceutical Co., Ltd. covering 30,000+ medical institution terminals across 17 Chinese provinces, complemented by direct field sales operations with 200+ employees, a DKSH partnership for Hong Kong and Macau, and wholly-owned subsidiaries in Shanghai, Beijing, Hong Kong, Zhuhai, Chengdu, and Cologne, Germany. Investors include CBC Group (lead Series D), Matrix Partners China, RTW Investments, HBM Healthcare Investments, Konruns Pharmaceutical, and state-backed funds Guoxin Guotong and Jiashan Guotou.

Short descriptiontext

Nuance Pharma is a Shanghai-based specialty biopharmaceutical company founded in 2014 that develops and commercializes first-in-class therapies in respiratory disease, emergency cardiac care, iron deficiency anemia, and pain management across China and Asia Pacific, operating both an integrated commercial platform with 5 marketed products and a late-stage pipeline of 4 clinical assets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty biopharmaceuticals, respiratory therapies, emergency care drugs, iron deficiency anemia treatment, pain management pharmaceuticals
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales
TypeOne Time License
Description

Commercialization of pharmaceutical products across respiratory, emergency care, iron deficiency anemia, and pain management in China and Asia Pacific markets. Products include NIFEREX (iron polysaccharide complex), ISOKET (isosorbide dinitrate), ELANTAN (isosorbide mononitrate), and OLPRINONE.

nuancepharma.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Strategic collaborations with global pharmaceutical companies generate upfront payments, development milestones, and commercialization royalties. Examples include $219M strategic collaboration with Verona Pharma for ensifentrine, $53M deal with Neumentum for NTM-001.

nuancepharma.com
3Milestone Payments
TypeTransaction Fee
Description

One-time milestone payments upon regulatory approvals. Received $1 million milestone payment from partner Altamira Therapeutics upon NMPA approval of Bentrio nasal spray in China.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nuance Pharma is a specialty care biopharmaceutical company that develops, in-licenses, and commercializes therapies across four therapeutic areas: respiratory diseases (COPD, neonatal RDS, allergic rhinitis), emergency care (cardiovascular conditions), iron deficiency anemia, and post-operative pain management. The company operates a dual-wheel model combining self-sustaining commercial operations for 5 marketed products with a late-stage clinical pipeline of 4 candidates, serving patients and healthcare providers in China and Asia Pacific.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Ohtuvayre met primary endpoint in ENHANCE-CHINA Phase 3 trial with statistically significant lung function improvement
+3 more records
Product overview1 text field

Nuance Pharma operates as a specialty care biopharma company with both commercialized products and a late-stage clinical pipeline. The portfolio spans four therapeutic areas: Respiratory (Ohtuvayre™ for COPD, Bentrio™ nasal spray, Actair® in development), Emergency Care (ISOKET®, ELANTAN®, OPRINONE for cardiovascular conditions), Iron Deficiency Anemia (NIFEREX®), and Pain Management (NTM-001 for post-operative pain). The company also has AeroFact™ in development for neonatal respiratory distress syndrome. Products are distributed across China mainland, Hong Kong, Macau, Taiwan, and other Asia Pacific territories under various licensing and distribution agreements with global partners including Verona Pharma, Aerogen Pharma, Altamira Therapeutics, Stallergenes Greer, and Neumentum.

Product and service9 records
1Ohtuvayre (ensifentrine)
CategoryRespiratory / COPD Therapy
Description

First-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Delivered via standard jet nebulizer for COPD maintenance treatment in adult patients. Licensed from Verona Pharma for Greater China.

2AeroFact
CategoryRespiratory / Neonatal Care
Description

Nasally inhaled surfactant combining bovine lung surfactant (Alveofact) with Aerogen's next-generation PDAP delivery technology for non-invasive treatment of neonatal respiratory distress syndrome (RDS) in preterm infants. Licensed from Aerogen Pharma for Greater China.

3Bentrio (倍愈朗)
CategoryRespiratory / Allergy Therapy
Description

Drug-free nasal spray that forms a protective gel layer on nasal mucosa to prevent contact of allergens and viruses with cells, binding particles and aiding their discharge. Indicated for allergic rhinitis and upper respiratory tract viral infection protection. Licensed from Altamira Therapeutics for China mainland, Hong Kong, Macau, and Korea.

4NTM-001 (Ketorolac)
CategoryPain Management
Description

Novel alcohol-free formulation of ketorolac in ready-to-use pre-mixed bag for continuous 24-hour IV infusion for post-operative pain treatment without opioid risks. Licensed from Neumentum for China.

5Actair
CategoryRespiratory / Allergy Immunotherapy
Description

Sublingual immunotherapy (SLIT) tablet for house dust mite (HDM)-induced allergic rhinitis and asthma. Licensed from Stallergenes Greer for development and commercialization in China.

6NIFEREX
CategoryIron Deficiency Anemia Therapy
Description

Iron polysaccharide complex capsules for treatment of iron deficiency anemia. Trademarked across multiple Asia Pacific territories; acquired by Nuance in 2019.

7ISOKET (异舒吉)
CategoryEmergency Care / Cardiovascular
Description

Isosorbide dinitrate injection and spray for treatment of acute heart failure, angina, and myocardial infarction in Mainland China.

8ELANTAN (异乐定)
CategoryEmergency Care / Cardiovascular
Description

Isosorbide mononitrate sustained-release capsules for treatment of heart failure, coronary heart disease, and angina.

9OPRINONE (奥普利农)
CategoryEmergency Care / Cardiovascular
Description

Olprinone hydrochloride injection for treatment of heart failure.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-08
Description

Exclusive long-term partnership for development and commercialization of Actair (house dust mite SLIT tablet) in China. Actair addresses allergic rhinitis and asthma, expanding Nuance's allergy portfolio.

Strategic tierImportantTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-28
Description

Partnership for Bentrio nasal spray launch in Hong Kong and Macau markets.

3Chinese Organization for Rare Disorders (CORD)
Strategic tierImportantTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

Collaboration for rare disease R&D advancement, clinical research, registry development, and patient education. Focus on neonatal respiratory distress syndrome.

nuancepharma.com
4Shanghai Pharmaceutical Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-06-16
Description

Strategic cooperation agreement for commercial distribution. Shanghai Pharma operates distribution network covering 30,000+ medical institution terminals across 17 provinces and cities in China.

nuancepharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-23
Description

Exclusive partnership to develop and commercialize AeroFact for treatment of neonatal respiratory distress syndrome (RDS) in Greater China. AeroFact combines bovine lung surfactant with Aerogen's PDAP delivery technology for non-invasive treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-10
Description

$219 million strategic collaboration to develop and commercialize ensifentrine (Ohtuvayre) in Greater China. Nuance paid $40 million upfront including $25M cash and $15M equity. Includes development, regulatory, and sales milestones plus royalties.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Shanghai-based clinical-stage biopharma that licenses and develops innovative therapies for the Asia-Pacific region. Closely mirrors Nuance's in-licensing-plus-regional-commercialization model across respiratory, anti-infectives and cardio/renal indications.

2HUTCHMED (China) Limited
TypeDirect peer
Description

Hong Kong- and Shanghai-based biopharma commercializing innovative oncology and specialty therapies in China and globally. Comparable as a China-focused innovative drug developer with both in-licensed and proprietary assets, late-stage pipeline, and dual US/HK listing.

3Shanghai Pharmaceuticals Holding
TypeBroad incumbent
Description

China's largest pharmaceutical distributor and a major domestic pharma manufacturer. Comparable as Nuance's strategic distribution partner (covering 30,000+ medical institutions) and as a broader incumbent operating across prescription drugs, distribution and healthcare services in China.

TypeDirect peer
Description

China- and US-based biopharma developing and commercializing immuno-oncology and specialty therapies through a similar in-license-plus-regional-development model. Directly comparable as a China-focused specialty biopharma at a similar stage.

TypeDirect peer
Description

Global oncology-focused biopharma headquartered in Beijing with major China commercial operations. Comparable as a large-scale Chinese biopharma running China clinical development of innovative therapies and commercializing through broad hospital channels.

TypeBroad incumbent
Description

Global biopharma leader with a major China commercial presence and dominant respiratory franchise (Symbicort, Breztri, Trixeo). Comparable as both a broader incumbent and former employer of Nuance's leadership — directly competitive in the China COPD market where Ohtuvayre will launch.

TypeDirect peer
Description

China-headquartered biopharmaceutical company developing and commercializing innovative medicines, primarily oncology but expanding into other specialty areas. Comparable as a Chinese specialty biopharma with both proprietary R&D and in-licensed assets and a HK-listed commercial platform.

8Sino Biopharmaceutical
TypeBroad incumbent
Description

Hong Kong-listed Chinese pharmaceutical conglomerate with broad therapeutic coverage including respiratory and cardiovascular products. Comparable as a broad incumbent in the same therapeutic areas (respiratory, cardiology, oncology) with established hospital sales force across China.

TypeDirect peer
Description

China-headquartered specialty biopharma commercializing in-licensed global therapies across oncology and specialty areas. Highly comparable in business model: in-licensing Western assets, running China clinical trials, and commercializing through a regional hospital-focused platform — just at a larger scale with a public listing.

TypeDirect peer
Description

China-based biopharmaceutical company developing innovative biologics across oncology and immunology. Comparable as a Chinese specialty biopharma combining proprietary R&D with in-licensing, with both commercial products and late-stage pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nuance Pharma

Specialty Biopharmaceuticalsnuancepharma.com

Nuance Pharma is a Shanghai-based specialty biopharmaceutical company founded in 2014 that develops and commercializes first-in-class therapies in respiratory disease, emergency cardiac care, iron deficiency anemia, and pain management across China and Asia Pacific, operating both an integrated commercial platform with 5 marketed products and a late-stage pipeline of 4 clinical assets.

What Nuance Pharma does

Nuance Pharma (also operating as Nuance Biotech, legal name 优锐医药科技(上海)有限公司) is a Shanghai-headquartered specialty care biopharmaceutical company founded in 2014 by Mark Lotter. The company operates a "dual-wheel model" that pairs self-sustaining commercial operations with late-stage clinical pipeline development across four therapeutic areas: respiratory disease (COPD, neonatal respiratory distress syndrome, and allergic rhinitis), emergency cardiac care, iron deficiency anemia, and post-operative pain management. End customers are primarily hospitals, healthcare providers, and patients across China and Asia Pacific markets.

The company's commercial portfolio includes NIFEREX (iron polysaccharide complex capsules), ISOKET (isosorbide dinitrate injection and spray), ELANTAN (isosorbide mononitrate sustained-release capsules), and OLPRINONE (olprinone hydrochloride) for heart failure — the latter three acquired through the 2021 Sino Health acquisition — alongside the recently launched Bentrio nasal spray for allergic rhinitis. The late-stage clinical pipeline features four differentiated assets: Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of PDE3 and PDE4 licensed from Verona Pharma, representing the first novel inhaled mechanism for COPD maintenance treatment in over 20 years; AeroFact, a non-invasive nasal surfactant delivery system for neonatal RDS combining bovine lung surfactant with Aerogen's patented PDAP aerosol technology; NTM-001 (ketorolac), a non-opioid alcohol-free IV infusion for post-operative pain licensed from Neumentum; and Actair, a sublingual immunotherapy tablet for house dust mite allergy licensed from Stallergenes Greer.

Nuance generates revenue through a mix of direct product sales in China and Asia Pacific, upfront licensing payments and milestone receipts from global partners (including a US$219 million Verona Pharma strategic collaboration), and ongoing royalties. Distribution is anchored by a strategic cooperation agreement with Shanghai Pharmaceutical Co., Ltd. covering 30,000+ medical institution terminals across 17 Chinese provinces, complemented by direct field sales operations with 200+ employees, a DKSH partnership for Hong Kong and Macau, and wholly-owned subsidiaries in Shanghai, Beijing, Hong Kong, Zhuhai, Chengdu, and Cologne, Germany. Investors include CBC Group (lead Series D), Matrix Partners China, RTW Investments, HBM Healthcare Investments, Konruns Pharmaceutical, and state-backed funds Guoxin Guotong and Jiashan Guotou.

Nuance Pharma firmographics

Firmographics
Name
Nuance Pharma
Legal name
优锐医药科技(上海)有限公司
Website
https://nuancepharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Nuance Pharma is a Shanghai-based specialty biopharmaceutical company founded in 2014 that develops and commercializes first-in-class therapies in respiratory disease, emergency cardiac care, iron deficiency anemia, and pain management across China and Asia Pacific, operating both an integrated commercial platform with 5 marketed products and a late-stage pipeline of 4 clinical assets.
Ownership category
akta.pro rank

Nuance Pharma industry classification

Industry
Product category
Specialty Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty biopharmaceuticals
  • Respiratory therapies
  • Emergency care drugs
  • Iron deficiency anemia treatment
  • Pain management pharmaceuticals

Where Nuance Pharma is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices6 records

Markets served

Nuance Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Product Sales: Commercialization of pharmaceutical products across respiratory, emergency care, iron deficiency anemia, and pain management in China and Asia Pacific markets. Products include NIFEREX (iron polysaccharide complex), ISOKET (isosorbide dinitrate), ELANTAN (isosorbide mononitrate), and OLPRINONE.
  2. Licensing and Milestone Payments: Strategic collaborations with global pharmaceutical companies generate upfront payments, development milestones, and commercialization royalties. Examples include $219M strategic collaboration with Verona Pharma for ensifentrine, $53M deal with Neumentum for NTM-001.
  3. Milestone Payments: One-time milestone payments upon regulatory approvals. Received $1 million milestone payment from partner Altamira Therapeutics upon NMPA approval of Bentrio nasal spray in China.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Nuance Pharma product offering

Product offering

Core offering

Nuance Pharma is a specialty care biopharmaceutical company that develops, in-licenses, and commercializes therapies across four therapeutic areas: respiratory diseases (COPD, neonatal RDS, allergic rhinitis), emergency care (cardiovascular conditions), iron deficiency anemia, and post-operative pain management. The company operates a dual-wheel model combining self-sustaining commercial operations for 5 marketed products with a late-stage clinical pipeline of 4 candidates, serving patients and healthcare providers in China and Asia Pacific.

Product overview

Nuance Pharma operates as a specialty care biopharma company with both commercialized products and a late-stage clinical pipeline. The portfolio spans four therapeutic areas: Respiratory (Ohtuvayre™ for COPD, Bentrio™ nasal spray, Actair® in development), Emergency Care (ISOKET®, ELANTAN®, OPRINONE for cardiovascular conditions), Iron Deficiency Anemia (NIFEREX®), and Pain Management (NTM-001 for post-operative pain). The company also has AeroFact™ in development for neonatal respiratory distress syndrome. Products are distributed across China mainland, Hong Kong, Macau, Taiwan, and other Asia Pacific territories under various licensing and distribution agreements with global partners including Verona Pharma, Aerogen Pharma, Altamira Therapeutics, Stallergenes Greer, and Neumentum.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ohtuvayre (ensifentrine) First-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Delivered via standard jet nebulizer for COPD maintenance treatment in adult patients. Licensed from Verona Pharma for Greater China.
  • AeroFact Nasally inhaled surfactant combining bovine lung surfactant (Alveofact) with Aerogen's next-generation PDAP delivery technology for non-invasive treatment of neonatal respiratory distress syndrome (RDS) in preterm infants. Licensed from Aerogen Pharma for Greater China.
  • Bentrio (倍愈朗) Drug-free nasal spray that forms a protective gel layer on nasal mucosa to prevent contact of allergens and viruses with cells, binding particles and aiding their discharge. Indicated for allergic rhinitis and upper respiratory tract viral infection protection. Licensed from Altamira Therapeutics for China mainland, Hong Kong, Macau, and Korea.
  • NTM-001 (Ketorolac) Novel alcohol-free formulation of ketorolac in ready-to-use pre-mixed bag for continuous 24-hour IV infusion for post-operative pain treatment without opioid risks. Licensed from Neumentum for China.
  • Actair Sublingual immunotherapy (SLIT) tablet for house dust mite (HDM)-induced allergic rhinitis and asthma. Licensed from Stallergenes Greer for development and commercialization in China.
  • NIFEREX Iron polysaccharide complex capsules for treatment of iron deficiency anemia. Trademarked across multiple Asia Pacific territories; acquired by Nuance in 2019.
  • ISOKET (异舒吉) Isosorbide dinitrate injection and spray for treatment of acute heart failure, angina, and myocardial infarction in Mainland China.
  • ELANTAN (异乐定) Isosorbide mononitrate sustained-release capsules for treatment of heart failure, coronary heart disease, and angina.
  • OPRINONE (奥普利农) Olprinone hydrochloride injection for treatment of heart failure.

Quantifiable outcome

  • Ohtuvayre met primary endpoint in ENHANCE-CHINA Phase 3 trial with statistically significant lung function improvement
  • +3 more outcomes

Companies that use Nuance Pharma

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Nuance Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nuance Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and important.

  • Stallergenes GreercoreStrategic or Co-development Partner · 8 September 2025Exclusive long-term partnership for development and commercialization of Actair (house dust mite SLIT tablet) in China. Actair addresses allergic rhinitis and asthma, expanding Nuance's allergy portfolio.
  • DKSHimportantChannel Partner/ Reseller/ Distributor · 28 November 2022Partnership for Bentrio nasal spray launch in Hong Kong and Macau markets.
  • Chinese Organization for Rare Disorders (CORD)importantStrategic or Co-development Partner · 1 July 2022Collaboration for rare disease R&D advancement, clinical research, registry development, and patient education. Focus on neonatal respiratory distress syndrome.
  • Shanghai Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 16 June 2022Strategic cooperation agreement for commercial distribution. Shanghai Pharma operates distribution network covering 30,000+ medical institution terminals across 17 provinces and cities in China.
  • Aerogen PharmacoreStrategic or Co-development Partner · 23 December 2021Exclusive partnership to develop and commercialize AeroFact for treatment of neonatal respiratory distress syndrome (RDS) in Greater China. AeroFact combines bovine lung surfactant with Aerogen's PDAP delivery technology for non-invasive treatment.
  • Verona PharmacoreStrategic or Co-development Partner · 10 June 2021$219 million strategic collaboration to develop and commercialize ensifentrine (Ohtuvayre) in Greater China. Nuance paid $40 million upfront including $25M cash and $15M equity. Includes development, regulatory, and sales milestones plus royalties.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Nuance Pharma competitors and assessment

Company assessment

Direct peers

  • Everest Medicines: Shanghai-based clinical-stage biopharma that licenses and develops innovative therapies for the Asia-Pacific region. Closely mirrors Nuance's in-licensing-plus-regional-commercialization model across respiratory, anti-infectives and cardio/renal indications.
  • HUTCHMED (China) Limited: Hong Kong- and Shanghai-based biopharma commercializing innovative oncology and specialty therapies in China and globally. Comparable as a China-focused innovative drug developer with both in-licensed and proprietary assets, late-stage pipeline, and dual US/HK listing.
  • Cstone Pharmaceuticals: China- and US-based biopharma developing and commercializing immuno-oncology and specialty therapies through a similar in-license-plus-regional-development model. Directly comparable as a China-focused specialty biopharma at a similar stage.
  • BeiGene: Global oncology-focused biopharma headquartered in Beijing with major China commercial operations. Comparable as a large-scale Chinese biopharma running China clinical development of innovative therapies and commercializing through broad hospital channels.
  • Innovent Biologics: China-headquartered biopharmaceutical company developing and commercializing innovative medicines, primarily oncology but expanding into other specialty areas. Comparable as a Chinese specialty biopharma with both proprietary R&D and in-licensed assets and a HK-listed commercial platform.
  • Zai Lab: China-headquartered specialty biopharma commercializing in-licensed global therapies across oncology and specialty areas. Highly comparable in business model: in-licensing Western assets, running China clinical trials, and commercializing through a regional hospital-focused platform — just at a larger scale with a public listing.
  • Akeso, Inc. China-based biopharmaceutical company developing innovative biologics across oncology and immunology. Comparable as a Chinese specialty biopharma combining proprietary R&D with in-licensing, with both commercial products and late-stage pipeline.

Broad incumbents

  • Shanghai Pharmaceuticals Holding: China's largest pharmaceutical distributor and a major domestic pharma manufacturer. Comparable as Nuance's strategic distribution partner (covering 30,000+ medical institutions) and as a broader incumbent operating across prescription drugs, distribution and healthcare services in China.
  • AstraZeneca: Global biopharma leader with a major China commercial presence and dominant respiratory franchise (Symbicort, Breztri, Trixeo). Comparable as both a broader incumbent and former employer of Nuance's leadership — directly competitive in the China COPD market where Ohtuvayre will launch.
  • Sino Biopharmaceutical: Hong Kong-listed Chinese pharmaceutical conglomerate with broad therapeutic coverage including respiratory and cardiovascular products. Comparable as a broad incumbent in the same therapeutic areas (respiratory, cardiology, oncology) with established hospital sales force across China.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Nuance Pharma social profiles

Digital presence

Nuance Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nuance Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Nuance Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Nuance Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nuance Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuance Pharma

What does Nuance Pharma do?

Nuance Pharma is a specialty care biopharmaceutical company that develops, in-licenses, and commercializes therapies across four therapeutic areas: respiratory diseases (COPD, neonatal RDS, allergic rhinitis), emergency care (cardiovascular conditions), iron deficiency anemia, and post-operative pain management. The company operates a dual-wheel model combining self-sustaining commercial operations for 5 marketed products with a late-stage clinical pipeline of 4 candidates, serving patients and healthcare providers in China and Asia Pacific.

Is Nuance Pharma a public or private company?

Nuance Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nuance Pharma founded?

Nuance Pharma was founded in 2014. It employs 11 to 50 people.

Where is Nuance Pharma based?

Nuance Pharma is headquartered in Shanghai, China, in the Asia region.

How does Nuance Pharma make money?

Three revenue lines are on record. Product Sales are the primary driver. The others are licensing and Milestone Payments and milestone Payments.

Who are Nuance Pharma's main competitors?

Direct peers on record are Everest Medicines, HUTCHMED (China) Limited, Cstone Pharmaceuticals, BeiGene, Innovent Biologics, Zai Lab and Akeso, Inc.. Broad incumbents are Shanghai Pharmaceuticals Holding, AstraZeneca and Sino Biopharmaceutical.

Does Nuance Pharma have an API?

No public API is recorded for Nuance Pharma.

What industry is Nuance Pharma in?

Nuance Pharma's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACNuance Pharma Announces First Patient Dosed in REACH Phase III Trial of STG320 (Actair®) in ChinaNuance Pharma announced the first patient dosed in the REACH Phase III trial of Actair for house dust mite-induced allergic rhinitis in China. The NMPA cleared the IND in May 2026, and the trial is a 12-month randomized, double-blind, placebo-controlled study. The company expects to introduce Actair in China as soon as possible.PR Newswire APACNuance Pharma Announces IND Clearance for Actair® Pivotal Clinical Trial in ChinaNuance Pharma received NMPA clearance to initiate a pivotal Phase III trial of Actair for house dust mite-induced allergic rhinitis in China. The 12-month randomized, double-blind, placebo-controlled study will evaluate efficacy and safety. The company plans to work with leading investigators to evaluate the treatment across China.PR Newswire APACNuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST JournalNuance Pharma announced that CHEST published results from its Phase 3 ENHANCE-CHINA trial of ensifentrine in Chinese COPD patients, showing lung function and dyspnea improvements. The data supported its NMPA NDA submitted in December 2025, with approval expected if granted.Media-outreachHKSTP Brings Together Life and Health Tech Leaders at CTC Marketplace Proving Ecosystem's Success in Driving Fundraising and Research CommercialisationHKSTP hosted the CTC Marketplace Showcase Event in Hong Kong, bringing together 110 industry leaders to discuss biotech fundraising, clinical trials, and research commercialisation. The event highlighted multiple success stories from the ecosystem, including Health Hope Pharma securing a licensing agreement with Gilead Sciences worth up to USD 82.5 million, Arthrosi Therapeutics achieving USD 153 million in Series E funding before being acquired for USD 1.5 billion, Nuance Pharma gaining approval for Ohtuvayre™ as the first COPD drug under Hong Kong's \u201c1+\u201d mechanism, and InxMed submitting its IPO application to the Hong Kong Stock Exchange after raising over USD 130 million.PR Newswire APACNuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, ChinaNuance Pharma announced that the Hong Kong Drug Office approved Ohtuvayre® (ensifentrine) for maintenance treatment of COPD in adult patients under the "1+ mechanism," marking the second regulatory approval outside of the U.S. FDA. Ohtuvayre is the first novel inhaled mechanism for COPD treatment in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects. The approval was based on the Global Phase 3 ENHANCE trials and the completed ENHANCE-CHINA trial, expanding access to patients in Hong Kong and Macau under Nuance's 2021 licensing agreement with Verona Pharma.ZoominfoNuance Communications - Overview, News & Similar companiesNuance Pharma announced that the Pharmaceutical Administration Bureau Macau approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease in adult patients. The company also reported statistically significant improvements in lung function from its Phase 3 ENHANCE-CHINA trial and plans to submit a New Drug Application in the second half of 2025.GlobeNewswireAltamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East AsiaAltamira Therapeutics and Nuance Pharma extended their exclusive license and distribution agreement for Bentrio nasal spray to seven additional countries in East and South East Asia, covering a combined population of over 630 million. Nuance has already launched Bentrio in Hong Kong and filed for Mainland China approval.GlobeNewswireVerona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate UpdateVerona Pharma reported Q1 2023 results with a net loss of $16.7 million and cash of $291.4 million. The company is on schedule to submit an NDA for ensifentrine in Q2 2023, with 12 abstracts and a symposium planned for ATS in May. Nuance Pharma enrolled the first subject in its Phase 3 trial in China.GlobeNewswireNuance Pharma Announces Dosing of First Patient in ENHANCENuance Pharma dosed the first subject in its ENHANCE Phase 3 trial for ensifentrine in COPD, with Phase 1 trials initiated in March 2023. The trial follows CDE clearance in August 2022, and Verona Pharma expects to submit an NDA in Q2 2023.PR NewswireNuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in ChinaNuance Pharma announced that China's Center for Drug Evaluation (CDE) has approved its Investigational New Drug (IND) application for MVA-BN RSV vaccine, enabling a pivotal Phase III clinical trial for respiratory syncytial virus prevention in adults in mainland China. The vaccine, developed by Bavarian Nordic using its MVA-BN platform technology and licensed exclusively to Nuance Pharma for China and select Asian markets, demonstrated up to 79% efficacy in preventing symptomatic RSV infections in prior Phase II trials. The company plans to conduct the Phase III study as an extension of Bavarian Nordic's ongoing global trial in 2023, with the potential to become the first adult RSV vaccine to market in China.